Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Ceftobiprole medocaril

Introduction

Overview

Overview

Ceftobiprole (Zeftera/Zevtera) is a fifth-generation[2] cephalosporin antibiotic with activity against methicillin-resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumoniae, Pseudomonas aeruginosa, and enterococci.[3][4][5] It was discovered by Basilea Pharmaceutica[6] and was developed by Johnson & Johnson Pharmaceutical Research and Development.[7] It has been shown to be statistically noninferior to the combination of vancomycin and ceftazidime for the treatment of skin and soft tissue infections.[8]

It has been described as a fifth-generation cephalosporin,[9][10] though acceptance for this terminology is not universal.

Pharmacology

Pharmacology

Like other cephalosporins, ceftobiprole inhibits bacterial growth by blocking penicillin-binding protein, a key enzyme involved in cell wall synthesis. Ceftobiprole inhibits the 2a penicillin-binding protein (PBP) of methicillin-resistant Staphylococcus aureus and the 2x PBP of Streptococcus pneumoniae,[4] as well as the classic PBP-2 of MSSA. Ceftobiprole is resistant to staphylococcal β-lactamase.[6]

Mode of administration

Mode of administration

Ceftobiprole is given intravenously; it cannot be given by mouth.

Regulatory approvals

Regulatory approvals

Ceftobiprole has been approved for use in Canada, Switzerland, and the European Union.[11] It is under review by regulatory authorities in the United States, Australia, Russia, and South Africa.[12] In November 2008, the US FDA declined to approve ceftobiprole, citing data integrity concerns with two of the supporting studies,[13] and prompting Basilea to sue Johnson & Johnson for breach of license agreement on February 2009.[14]

Synonyms

Synonyms

  • RO0639141-000[6]
  • BAL9141[15]
  • Ceftobiprole medocaril
References

References

  1. ↑ WHO International Working Group for Drug Statistics Methodology (August 27, 2008). “ATC/DDD Classification (FINAL): New ATC 5th level codes”. WHO Collaborating Centre for Drug Statistics Methodology. Retrieved 2008-09-05.
  2. ↑ Kollef MH (December 2009). “New antimicrobial agents for methicillin-resistant Staphylococcus aureus”. Crit Care Resusc. 11 (4): 282–6. PMID 20001879.
  3. ↑ Yun HC, Ellis MW, Jorgensen JH (2007). “Activity of ceftobiprole against community-associated methicillin-resistant Staphylococcus aureus isolates recently recovered from US military trainees”. Diagnostic Microbiology and Infectious Disease. 59 (4): 463–6. doi:10.1016/j.diagmicrobio.2007.06.023. PMID 17911001.
  4. ↑ 4.0 4.1 Widmer A (2008). “Ceftobiprole: A new option for treatment of skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus“. Clin Infect Dis. 46 (5): 656–8. doi:10.1086/526528. PMID 18225983.
  5. ↑ Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS (2008). “A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections”. Clin Infect Dis. 46 (5): 647–55. doi:10.1086/526527. PMID 18225981.
  6. ↑ 6.0 6.1 6.2 Hebeisen P, Heinze-Krauss I, Angehrn P; et al. (2001). “In vitro and in vivo properties of Ro63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci”. Antimicrob Agents Chemother. 45 (3): 825–36. doi:10.1128/AAC.45.3.825-836.2001. PMC 90381. PMID 11181368.
  7. ↑ Basilea.com
  8. ↑ Noel, Gary J.; Karen Bush; Partha Bagchi; Juliana Ianus; Richard S. Strauss (2008). “A Randomized, Double-Blind Trial Comparing Ceftobiprole Medocaril with Vancomycin plus Ceftazidime for the Treatment of Patients with Complicated Skin and Skin-Structure Infections”. Clin Infect Dis. 46 (5): 647-655. doi:10.1086/526527. PMID 18225981. |access-date= requires |url= (help)
  9. ↑ Widmer AF (March 2008). “Ceftobiprole: a new option for treatment of skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus”. Clin. Infect. Dis. 46 (5): 656–8. doi:10.1086/526528. PMID 18225983.
  10. ↑ Kosinski MA, Joseph WS (July 2007). “Update on the treatment of diabetic foot infections”. Clin Podiatr Med Surg. 24 (3): 383–96, vii. doi:10.1016/j.cpm.2007.03.009. PMID 17613382.
  11. ↑ Basilea antibiotic to treat pneumonia wins European backing. Reuters, ZURICH | Wed Oct 23, 2013.
  12. ↑ Basilea superbug drug approved in Canada, Reuters News, June 30, 2008
  13. ↑ http://www.dancewithshadows.com/pillscribe/ceftobiprole-antibiotic-to-fight-tougher-bacterial-infections-fails-to-win-approval-in-us/
  14. ↑ “Basilea Pharmaceutica Ltd. announces that the U.S. Food and Drug Administration (FDA) issued to the sponsor, Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (Johnson & Johnson PRD), a Complete Response Letter on ceftobiprole for the treatment of complicated skin and skin structure infections (cSSSI” (Press release). Basilea Pharmaceutica. 2009-07-02. Retrieved February 2, 2010.
  15. ↑ Jones RN, Deshpande LM, Mutnick AH, Biedenbach DJ (2002). “In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci”. J Antimicrob Chemother. 50 (6): 915–932. doi:10.1093/jac/dkf249. PMID 12461013.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]